News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Related Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News KBRA Releases Research – Structured Credit Trend Watch: CLO Issuance in Bloom—First Quarter Record for Middle Market Machine Learning News Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting Cybersecurity News Sheppard Mullin Lands Healthcare Partner Stephanie Marcantonio in New York News T-Mobile Unveils BIG Moves to Help Small Businesses Grow News EasyKnock Announces Partnership With Piñata News Enable Drives Millions in Rebate ROI, 100% Growth of Rebate Programs According to Canalys Ecosystem Multiplier Study
